Rodríguez RH, Samada SM, Hernández PJC, Pérez GT, Cruz HZD, Chao GL

Language: Spanish
References: 14
Page: 4-12
PDF size: 55.82 Kb.

ABSTRACT

Introduction. Autoimmune hepatitis is a chronic liver disease that evolves towards liver cirrhosis. A timely immunosuppressive therapy permits to stop or delay the development of the disease to more advanced stages. Methods. It was a descriptive, retrospective and prospective study of 24 patients with a diagnosis of autoimmune hepatitis. They were seen in outpatients at the Center of Medical-Surgical Research between November 2010 and June 2013. They received treatment for an average period of seven years, with the aim of determining clinical and demographic characteristics, as well as the relationship between the response to the treatment and the development of the disease. Results. All the studied patients were females and the average age was 36 years. At diagnosis, the predominant clinical stage was compensated liver cirrhosis. When evaluated, five patients were at the chronic hepatitis stage, four of them had had a complete response to treatment. Thirteen patients were in the compensated liver cirrhosis stage, out of whom ten responded to treatment. Out of the six patients that were not compensated, none responded to treatment completely. Regarding the development of the disease, out of the 14 patients that had a complete response to the treatment, ten remained in the same stage, four improved and none progressed to a more advanced stage of the illness. Conclusions. The response to treatment in patients with autoimmune hepatitis is strongly related to the non-progression of the disease.

REFERENCES

1. Rodrigo R. Hepatitis autoinmune. En: Berenguer J, editor. Gastroenterología y Hepatología. 3era Ed. Barcelona: Elselvier Science; 2002. p. 630-7.

2. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Prevention for effects adverse hepatology. Americ Associat Diseas. 2010;51(2):193-213.

3. Tejedor M, Martín RM, Martínez J, Albillos A. Avances en la etiopatogenia, diagnóstico y tratamiento de la hepatitis autoinmune. Medicine. 2012;11(9):541-8.

4. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterol. 2010;139:58-72.

5. Morillas RM, Planas R. Hepatitis autoinmune. En: Montoro MA, García JC, editores. Problemas comunes en la práctica clínica. 2da Ed. Madrid, España: Asociación Española para el Estudio del Hígado; 2012. p. 747-57.

6. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simpliied diagnostic criteria for autoimmune hepatitis. Hepatology. 2008;48:169-76.

7. Mohamadneja M, Malekzadeh R, Nasseri S, Rakhshani N, Mahoma S. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005;50:547-51.

8. Gleeson D, Heneghan M. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-29.

9. Fallalak H , Akbar H , Qari Y. Experience of clinical presentation response to treatment and prognosis in Saudi Arabia. Saudi Gastro. 2010;16(2):95-9.

10. Valera JM, Smok G, Márquez S. Regresión histológica de la fibrosis hepática con tratamiento inmunosupresor en hepatitis autoinmune. Gastroenterol Hepatol. 2011;34(1):10-5.

11. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40:646-52.

12. Friedman SL. Molecular regulation of hepatic fibrosis, anintegrated cellular response to tissue injury. J Biol Chem. 2000;275:2247-50.

13. Issa R, Williams E, Trim N, Kendall T, Arthur MJ , Reichen J, et al. Apoptosis of hepatic stellate cells: involvement in resolu-tion of biliary fibrosis and regulation by soluble growth factors. Gut. 2001;48:548-57.

14. Mieli-vergani G, Vergani D. Autoimmune hepatitis. Rev Gastroenterol Hepatol. 2010;8:320-9.